Review of the role of erythropoietin in critical leg ischemia

Angiology

Volumn 61, Issue 6, 2010, Pages 541-550

  Joshi, Dhiraj ^a   Tsui, Janice ^a   Ho, Teik K ^a   Selvakumar, Sadasivam ^a   Abraham, David J ^a   Baker, Daryll M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

angiogenesis; apoptosis; critical leg ischemia; erythropoietin; skeletal muscle

Indexed keywords

ASIALO ERYTHROPOIETIN; CARBAMYLATED ERYTHROPOIETIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW CELL; COMPETITIVE INHIBITION; CRITICAL LEG ISCHEMIA; DRUG EFFICACY; DRUG HALF LIFE; HEMATOCRIT; HUMAN; IMMUNOHISTOCHEMISTRY; LEG ISCHEMIA; MUSCLE ISCHEMIA; PROTECTION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SKELETAL MUSCLE; SYSTEMATIC REVIEW; THERAPY EFFECT; WESTERN BLOTTING;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; APOPTOSIS; ERYTHROPOIETIN; HUMANS; ISCHEMIA; LEG; NEOVASCULARIZATION, PHYSIOLOGIC; REGIONAL BLOOD FLOW;

EID: 77955019956     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319709358697     Document Type: Article

References (70)

1. Second European Consensus Document on chronic critical leg ischemia. Circulation. 1991 ; 84 (4 suppl). IV1 - IV26.
2. Albers M., Fratezi AC, De LN Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. J Vasc Surg. 1992 ; 16 (1). 54-59.
3. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori. Ann Intern Med. 1999 ; 130 (5). 412-421.
4. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double-blind placebo controlled study. U.K. Severe Limb Ischaemia Study Group. Eur J Vasc Surg. 1991 ; 5 (5). 511-516.
5. Marchesi S., Pasqualini L., Lombardini R., et al. Prostaglandin E1 improves endothelial function in critical limb ischemia. J Cardiovasc Pharmacol. 2003 ; 41 (2). 249-253.
6. Robless P., Mikhailidis DP, Stansby GP Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. 2008 ; 1: CD003748.
7. Miyake T., Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977 ; 252 (15). 5558-5564.
8. Lin FK, Suggs S., Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985 ; 82 (22). 7580-7584.
9. Davis JM, Arakawa T., Strickland TW, Yphantis DA Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry. 1987 ; 26 (9). 2633-2638.
10. Winearls CG Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin. Drugs. 1989 ; 38 (3). 342-345.
11. Ho TK, Rajkumar V., Ponticos M., et al. Increased endogenous angiogenic response and hypoxia-inducible factor-1alpha in human critical limb ischemia. J Vasc Surg. 2006 ; 43 (1). 125-133.
12. Ebert BL, Bunn HF Regulation of the erythropoietin gene. Blood. 1999 ; 94 (6). 1864-1877.
13. Rezaeian F., Wettstein R., Amon M., et al. Erythropoietin protects critically perfused flap tissue. Ann Surg. 2008 ; 248 (6). 919-929.
14. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002 ; 8 (8). 495-505.
15. Riksen NP, Hausenloy DJ, Yellon DM Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci. 2008 ; 29 (5). 258-267.
16. Yamaji R., Okada T., Moriya M., et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem. 1996 ; 239 (2). 494-500.
17. Nagao M., Matsumoto S., Masuda S., Sasaki R. Effect of tunicamycin treatment on ligand binding to the erythropoietin receptor: conversion from two classes of binding sites to a single class. Blood. 1993 ; 81 (10). 2503-2510.
18. Leist M., Ghezzi P., Grasso G., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004 ; 305 (5681). 239-242.
19. Law ML, Cai GY, Lin FK, et al. Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc Natl Acad Sci U S A. 1986 ; 83 (18). 6920-6924.
20. Maiese K., Li F., Chong ZZ New avenues of exploration for erythropoietin. JAMA. 2005 ; 293 (1). 90-95.
21. Lacombe C., Da Silva JL, Bruneval P., et al. Identification of tissues and cells producing erythropoietin in the anemic mouse. Contrib Nephrol. 1988 ; 66: 17-24.
22. Ebert BL, Bunn HF Regulation of the erythropoietin gene1. Blood. 1999 ; 94 (6). 1864-1877.
23. Elliott S., Lorenzini T., Chang D., Barzilay J., Delorme E. Mapping of the active site of recombinant human erythropoietin. Blood. 1997 ; 89 (2). 493-502.
24. Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology. 1985 ; 116 (6). 2293-2299.
25. Erbayraktar S., Grasso G., Sfacteria A., et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo7. Proc Natl Acad Sci U S A. 2003 ; 100 (11). 6741-6746.
26. Budarf M., Huebner K., Emanuel B., et al. Assignment of the erythropoietin receptor (EPOR) gene to mouse chromosome 9 and human chromosome 19. Genomics. 1990 ; 8 (3). 575-578.
27. Bazan JF A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochem Biophys Res Commun. 1989 ; 164 (2). 788-795.
28. Brines M., Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005 ; 6 (6). 484-494.
29. Brines M., Grasso G., Fiordaliso F., et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004 ; 101 (41). 14907-14912.
30. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ Signal transduction in the erythropoietin receptor system. Exp Cell Res. 1999 ; 253 (1). 143-156.
31. Anagnostou A., Lee ES, Kessimian N., Levinson R., Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990 ; 87 (15). 5978-5982.
32. Ammarguellat F., Gogusev J., Drueke TB Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant. 1996 ; 11 (4). 687-692.
33. Wright GL, Hanlon P., Amin K., Steenbergen C., Murphy E., Arcasoy MO Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004 ; 18 (9). 1031-1033.
34. Juul SE, Anderson DK, Li Y., Christensen RD Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res. 1998 ; 43 (1). 40-49.
35. Liu T., Allaf ME, Lagoda G., Burnett AL Erythropoietin receptor expression in the human urogenital tract: immunolocalization in the prostate, neurovascular bundle and penis. BJU Int. 2007 ; 100 (5). 1103-1106.
36. Yokomizo R., Matsuzaki S., Uehara S., Murakami T., Yaegashi N., Okamura K. Erythropoietin and erythropoietin receptor expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod. 2002 ; 8 (5). 441-446. (Pubitemid 34567922)
37. Lundby C., Hellsten Y., Jensen MB, Munch AS, Pilegaard H. Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle. J Appl Physiol. 2008 ; 104 (4). 1154-1160.
38. Ogilvie M., Yu X., Nicolas-Metral V., et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem. 2000 ; 275 (50). 39754-39761.
39. Bodine-Fowler S. Skeletal muscle regeneration after injury: an overview. J Voice. 1994 ; 8 (1). 53-62.
40. Nakano M., Satoh K., Fukumoto Y., et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res. 2007 ; 100 (5). 662-669.
41. Ozawa T., Kato K., Toba K., et al. Serum erythropoietin level as a marker of limb ischemia. Int J Cardiol. 2008 ; 130 (1). 106-108.
42. Spandou E., Papoutsopoulou S., Soubasi V., et al. Hypoxia-ischemia affects erythropoietin and erythropoietin receptor expression pattern in the neonatal rat brain. Brain Res. 2004 ; 1021 (2). 167-172.
43. Socolovsky M., Nam H., Fleming MD, Haase VH, Brugnara C., Lodish HF Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001 ; 98 (12). 3261-3273.
44. Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol. 2007 ; 150 (7). 839-850.
45. Majno G., Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995 ; 146 (1). 3-15.
46. Barani J., Nilsson JA, Mattiasson I., Lindblad B., Gottsater A. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg. 2005 ; 42 (1). 75-80.
47. Mitchell RG, Duscha BD, Robbins JL, et al. Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease. Vasc Med. 2007 ; 12 (4). 285-290.
48. Guneli E., Cavdar Z., Islekel H., et al. Erythropoietin protects the intestine against ischemia/reperfusion injury in rats. Mol Med. 2007 ; 13 (9-10). 509-517.
49. Rotter R., Menshykova M., Winkler T., et al. Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue. J Orthop Res. 2008 ; 26 (12). 1618-1626.
50. Carlini RG, Alonzo EJ, Dominguez J., et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int. 1999 ; 55 (2). 546-553.
51. Hallstrom S., Gasser H., Neumayer C., et al. S-nitroso human serum albumin treatment reduces ischemia/reperfusion injury in skeletal muscle via nitric oxide release. Circulation. 2002 ; 105 (25). 3032-3038.
52. Akimoto T., Kusano E., Inaba T., et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway1. Kidney Int. 2000 ; 58 (1). 269-282.
53. Contaldo C., Meier C., Elsherbiny A., et al. Human recombinant erythropoietin protects the striated muscle microcirculation of the dorsal skinfold from postischemic injury in mice. Am J Physiol Heart Circ Physiol. 2007 ; 293 (1). H274 - H283.
54. Guneli E., Cavdar Z., Islekel H., et al. Erythropoietin protects the intestine against ischemia/reperfusion injury in rats. Mol Med. 2007 ; 13 (9-10). 509-517.
55. Beleslin-Cokic BB, Cokic VP, Yu X., Weksler BB, Schechter AN, Noguchi CT Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004 ; 104 (7). 2073-2080.
56. Calapai G., Marciano MC, Corica F., et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol. 2000 ; 401 (3). 349-356.
57. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000 ; 6 (4). 389-395.
58. Form DM, Pratt BM, Madri JA Endothelial cell proliferation during angiogenesis. In vitro modulation by basement membrane components. Lab Invest. 1986 ; 55 (5). 521-530.
59. Folkman J., Haudenschild C. Angiogenesis by capillary endothelial cells in culture. Trans Ophthalmol Soc U K. 1980 ; 100 (3). 346-353.
60. Stokes CL Endothelial cell migration and chemotaxis in angiogenesis. EXS. 1992 ; 61: 118-124.
61. Kertesz N., Wu J., Chen TH, Sucov HM, Wu H. The role of erythropoietin in regulating angiogenesis. Dev Biol. 2004 ; 276 (1). 101-110.
62. Heeschen C., Aicher A., Lehmann R., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003 ; 102 (4). 1340-1346.
63. Scholz D., Schaper W. Enhanced arteriogenesis in mice overexpressing erythropoietin. Cell Tissue Res. 2006 ; 324 (3). 395-401.
64. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 1995 ; 47 (3). 740-745.
65. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 1993 ; 43 (5). 1010-1014.
66. Nakano M., Satoh K., Fukumoto Y., et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res. 2007 ; 100 (5). 662-669.
67. Ribatti D., Presta M., Vacca A., et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999 ; 93 (8). 2627-2636.
68. Tateishi-Yuyama E., Matsubara H., Murohara T., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002 ; 360 (9331). 427-435.
69. Mori S., Sawada T., Kubota K. Asialoerythropoietin is a strong modulator of angiogenesis by bone-marrow cells. J Invest Surg. 2007 ; 20 (6). 357-362.
70. Ozawa T., Toba K., Kato K., et al. Erythroid cells play essential roles in angiogenesis by bone marrow cell implantation. J Mol Cell Cardiol. 2006 ; 40 (5). 629-638.